
Later this month, the FDA will vote on KarXT, a novel muscarinic acetylcholine receptor agonist.

Later this month, the FDA will vote on KarXT, a novel muscarinic acetylcholine receptor agonist.

Here’s what Dr Moffic plans to cover in this week…

Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?


A therapist asks a question that makes me glimpse the eternal.

In this CME article, learn how best to provide end-of-life care to patients with psychiatric disorders.

John Krystal, MD, explores the future of ketamine and psychedelics in psychiatry, shedding light on their potential to improve patient care by increasing options treatment options.

The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.

"One September morning, the day I started medical school, I placed a two-foot specimen in my sunny south window."

Are we reliving the evolution of managed care from the 1980s and 1990s?

Meeting the needs of the dying and their families requires a deep and clear understanding of competent and compassionate care.

Is the complex posttraumatic stress disorder diagnosis being used to avoid the diagnosis of borderline personality disorder?

How can we improve rural mental health?

If psychiatrists of different religions and spiritual beliefs coupled with psychological insights cannot overcome conflict and achieve peace, who can?

A trio of problem unite in September...

Intensive caring offers a way of addressing suffering designed to better meet the needs of patients and families.

Premenstrual dysphoric disorder: a condition that is often underestimated and mistaken for typical premenstrual symptoms or mood swings.

Assisted outpatient treatment is not intended to replace comprehensive, easy-to-access, voluntary treatment. Here's why we need it, according to one expert.

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.

Far less attention is paid by mental health clinicians to aspects of death and dying. This Psychiatric Times Death and Dying Special Report helps fill some of that gap.

A psychiatrist ponders: What happens when your career, which usually brings you joy and gratitude, paradoxically becomes a source of great stress?

The Boomerang Effect: when an individual’s attempt to persuade someone else has the opposite effect, coming back to haunt the messenger, like a boomerang thrown correctly comes back toward the thrower.

The emergence of psychiatric mental health nurse practitioners as key players in mental health care delivery has become increasingly apparent.

"...the heart-shaped ficus leaves dropping like sad notes from a Spanish song..."

Should ketamine be used at all when FDA-approved Spravato is available and insurance will pay for it?

We cannot learn from history unless we talk about it…

"Poetry arrived in search of me."

The season of the cat…

How can agitation mimic various psychiatric illnesses?

Psychedelics: we first must enlarge our knowledge of how these work, what clinical conditions should be targeted, and how different psychedelics compare to each other.